Overexpression of miRNA-497 inhibits tumor angiogenesis by targeting VEGFR2

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Tu, Yingfeng ^a,b,d   Liu, Li ^b   Zhao, Dongliang ^a,b   Liu, Youbin ^c   Ma, Xiaowei ^d   Fan, Yuhua ^b   Wan, Lin ^a,b   Huang, Tao ^a,b   Cheng, Zhen ^d   Shen, Baozhong ^a,b  

^a China Key Laboratory of Chemical Engineering Process and Technology for High Efficiency   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; MIRN497 MICRORNA, HUMAN; RAF PROTEIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL; APOPTOSIS; CELL PROLIFERATION; CELL TRANSFORMATION; DISEASE MODEL; DRUG SCREENING; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; RAF KINASES; RNA INTERFERENCE; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941087546     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13827     Document Type: Article

References (41)

1. Mura, M. et al. Identification and angiogenic role of the novel tumor endothelial marker CLEC14A. Oncogene 31, 293-305 (2012).
2. Awazu, Y. et al. Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinase. Cancer science 104, 486-494 (2013).
3. Finley, S. D. & Popel, A. S. Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms. The AAPS journal 14, 500-509 (2012).
4. Amini, A., Masoumi Moghaddam, S., Morris, D. L. & Pourgholami, M. H. The critical role of vascular endothelial growth factor in tumor angiogenesis. Current cancer drug targets 12, 23-43 (2012).
5. Chatterjee, S. et al. Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. The Journal of clinical investigation 123, 3183 (2013).
6. Zhao, D. et al. In vivo monitoring of angiogenesis inhibition via down-regulation of mir-21 in a VEGFR2-luc murine breast cancer model using bioluminescent imaging. PLoS One 8, e71472 (2013).
7. Coultas, L., Chawengsaksophak, K. & Rossant, J. Endothelial cells and VEGF in vascular development. Nature 438, 937-945 (2005).
8. Law, A. Y. & Wong, C. K. Stanniocalcin-1 and -2 promote angiogenic sprouting in HUVECs via VEGF/VEGFR2 and angiopoietin signaling pathways. Mol Cell Endocrinol 374, 73-81 (2013).
9. Hata, Y. et al. Antiangiogenic properties of fasudil, a potent Rho-Kinase inhibitor. Japanese journal of ophthalmology 52, 16-23 (2008).
10. Murphy, D. A. et al. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). The American journal of pathology 169, 1875-1885 (2006).
11. Somanath, P. R., Razorenova, O. V., Chen, J. & Byzova, T. V. Akt1 in endothelial cell and angiogenesis. Cell Cycle 5, 512-518 (2006).
12. Jin, J. et al. Vascular endothelial growth factor regulates primate choroid-retinal endothelial cell proliferation and tube formation through PI3K/Akt and MEK/ERK dependent signaling. Mol Cell Biochem 381, 267-272 (2013).
13. Silvestre, J. S. et al. Lactadherin promotes VEGF-dependent neovascularization. Nature medicine 11, 499-506 (2005).
14. Shih, M. C. et al. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Oncogene 31, 2389-2400 (2012).
15. Yap, T. A. et al. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Current opinion in pharmacology 8, 393-412 (2008).
16. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004).
17. Li, D. et al. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res 17, 1722-1730 (2011).
18. Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005).
19. Dvinge, H. et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 497, 378-382 (2013).
20. Yoo, J. K. et al. The novel miR-9500 regulates the proliferation and migration of human lung cancer cells by targeting Akt1. Cell death and differentiation 21, 1150-1159 (2014).
21. Qian, X. et al. MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle 12, 1385-1394 (2013).
22. Zhou, B. et al. MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth. Cancer Lett 333, 159-169 (2013).
23. Cha, S. T. et al. MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis. Cancer Res 70, 2675-2685 (2010).
24. Liu, X., Cheng, Y., Yang, J., Xu, L. & Zhang, C. Cell-specific effects of miR-221/222 in vessels: molecular mechanism and therapeutic application. J Mol Cell Cardiol 52, 245-255 (2012).
25. Fang, L. et al. MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-beta8. Oncogene 30, 806-821(2011).
26. Lee, D. Y., Deng, Z., Wang, C. H. & Yang, B. B. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci U S A 104, 20350-20355 (2007).
27. Yadav, S. et al. miR-497 and miR-302b regulate ethanol-induced neuronal cell death through BCL2 protein and cyclin D2. J Biol Chem 286, 37347-37357 (2011).
28. Zhu, W. et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 29, 384-391 (2012).
29. Guo, S. T. et al. MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene 32, 1910-1920 (2013).
30. Zheng, D., Radziszewska, A. & Woo, P. MicroRNA 497 modulates interleukin 1 signalling via the MAPK/ERK pathway. FEBS letters 586, 4165-4172 (2012).
31. Shen, L. et al. miR-497 induces apoptosis of breast cancer cells by targeting Bcl-w. Experimental and therapeutic medicine 3: 475-480 (2012).
32. Si, M. L. et al. miR-21-mediated tumor growth. Oncogene 26, 2799-2803 (2007).
33. Nicoli, S. et al. MicroRNA-mediated integration of haemodynamics and Vegf signalling during angiogenesis. Nature 464, 1196-1200 (2010).
34. Creevey, L. et al. MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1. Molecular cancer 12, 23 (2013).
35. Zhao, W. Y. et al. Downregulation of miR-497 promotes tumor growth and angiogenesis by targeting HDGF in non-small cell lung cancer. Biochemical and biophysical research communications 435, 466-471(2013).
36. Zhao, G. et al. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PloS one 8, e53906 (2013).
37. Sylvester, P. W. & Ayoub, N. M. Tocotrienols Target PI3K/Akt Signaling in Anti-Breast Cancer Therapy. Anti-cancer agents in medicinal chemistry 13, 1039-1047 (2013).
38. Ehling, J., Lammers, T. & Kiessling, F. Non-invasive imaging for studying anti-angiogenic therapy effects. Thrombosis and haemostasis 109, 375-390 (2013).
39. Lemasson, B. et al. Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects. NMR in biomedicine 24, 473-482 (2011).
40. Kaijzel, E. L., van der Pluijm, G. & Lowik, C. W. Whole-body optical imaging in animal models to assess cancer development and progression. Clinical cancer research : an official journal of the American Association for Cancer Research 13, 3490-3497 (2007).
41. Zhang, N., Fang, Z., Contag, P. R., Purchio, A. F. & West, D. B. Tracking angiogenesis induced by skin wounding and contact hypersensitivity using a Vegfr2-luciferase transgenic mouse. Blood 103, 617-626 (2004).